News & analysis on the clinical development and manufacture of large molecule drugs
Alector - Various
By Ben Hargreaves
- Last updated on
Privately held biotech, Alector, has revealed a number of additions to its board of directors, with some impressive credentials behind them. The three new board members are David Wehner (pictured), CFO of Facebook, Richard Scheller, CSO of 23andMe, and Louis Lavigne, CFO of Genentech.
“David, Richard and Lou bring extensive technical and operational expertise to our team, as we continue our progress towards becoming a fully integrated biotechnology company,” said Arnon Rosenthal, CEO of Alector.
The San Francisco based biotech is working on preventing ‘diseases of ageing’ by finding the genetic causes of disease and harnessing the immune system to prevent degeneration of certain conditions. In particular, the firm recently initiated a Phase I trial for the treatment of Alzheimer’s disease.